Fredag 29 November | 17:47:19 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-18 08:00 Bokslutskommuniké 2024
2024-12-13 N/A Extra Bolagsstämma 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 - Årsstämma
2024-02-23 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-04 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2023-01-12 - Extra Bolagsstämma 2022
2022-11-04 - Kvartalsrapport 2022-Q3
2022-08-05 - Kvartalsrapport 2022-Q2
2022-05-30 - Kvartalsrapport 2022-Q1
2022-05-23 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-11-08 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-13 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 - Årsstämma
2019-04-24 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-16 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-13 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-09 - Bokslutskommuniké 2016
2016-11-04 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga patienttillstånd inom kroniska inflammatoriska sjukdomar, samt diverse ledskador. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2024-02-23 07:50:00

” We have excellent opportunities before us, and we remain focused on delivering patient, company and shareholder value,” said Torbjørn Bjerke, CEO.

October – December 2023

  • The Group's net sales amounted to SEK 0 (0) thousand.
  • Operating expenses amounted to SEK 91,062 (30,523) thousand, an increase of 198%.
  • The Group's loss after tax amounted to SEK 90,543 (30,477) thousand.
  • The Group's earnings per share before and after dilution amounted to SEK -2.58 (-1.06).
  • Cash flow from operating activities amounted to SEK -20,395 (-22,306) thousand.
  • Cash flow from financing activities amounted to SEK 54,561 (76,025) thousand.
  • Cash flow for the period amounted to SEK 34,166 (53,747) thousand.
  • Cash and cash equivalents at the end of the period amounted to SEK 62,395 (108,245) thousand.

January – December 2023

  • The Group's net sales amounted to SEK 0 (0) thousand.
  • Operating expenses amounted to SEK 224,496 (105,705) thousand, an increase of 112%, driven primarily by the two clinical studies in RA and higher administrative costs caused by the acquisition of TXP and write down of goodwill.
  • The Group's loss after tax amounted to SEK 215,810 (99,205) thousand.
  • The Group's earnings per share before and after dilution amounted to SEK -6.64 (-3.60).
  • Cash flow from operating activities amounted to SEK -100,177 (-117,555) thousand.
  • Cash flow from financing activities amounted to SEK 53,984 (200,712) thousand.
  • Cash flow for the period amounted to SEK -45,823 (83,184) thousand

Significant events during the period

  • Oct 3 - SynAct announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP.
  • Oct 11 - SynAct carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million.
  • Oct 12 - SynAct publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm.
  • Oct 31 - Change in number of shares and votes in SynAct Pharma. As of October 31, 2023, the total number of shares and votes in SynAct Pharma AB amounts to 35,570,980.
  • Nov 1 - SynAct announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate.

Significant events after the end of the period

  • Jan 28 - The Board of Directors of SynAct Pharma AB has
  • received a request to convene an EGM
  • Jan 30 - SynAct expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors.
  • Feb 1 - SynAct appoints Kirsten Harting as Chief Medical Officer.
  • Feb 7 - Notice of extraordinary general meeting in SynAct Pharma AB. Upon request by >10% of the shareholders, an extra general meeting has been set to March 20, 2024.
  • Feb. 22 - SynAct announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis.

For further information about SynAct Pharma AB, please contact:
Torbjørn Bjerke
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Email: TBJE@synactpharma.com
Email: investor.relations@synactpharma.com
 
Björn Westberg
CFO, SynAct Pharma AB 
Phone: +46 703 33 91 23
Email: BWE@synactpharma.com